Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs
LEXINGTON, Mass., Feb. 12, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) has been awarded five new patents that expand the intellectual property protection for Pulmatrix's PUR1800 and PUR5700 programs. These patents expand the intellectual property protection for Pulmatrix's novel Inhaled Narrow Spectrum Kinase Inhibitors which were in licensed from Janssen in June 2017.
The US Patent Office granted US Patent No. 9,993,478 B2, which claims dry powder formulations that contain certain narrow spectrum kinase inhibitors as the active pharmaceutical ingredient and cover dry powder formulations of the in licensed compound RV-1162. RV-1162 is the active pharmaceutical ingredient in PUR1800.
Pulmatrix has also received four new patents for the compound RV-7031, the active pharmaceutical ingredient in PUR5700. In the US, the United States Patent Office granted US Patent Nos. 9,884,845 B2 and 10,045,980 B2 which contain claims that cover RV-7031 as a composition of matter and also claims that cover dry powder formulations of RV-7031. In the EU, the European Patent Office granted European Patents Nos. 3105222 B1 and 3105223 B1 with claims that cover RV-7031 as a composition of matter and claims that cover dry powder formulations of RV-7031 alone or in combination with other therapeutic agents.
"These granted patents for our novel anti-inflammatory narrow spectrum kinase inhibitor molecules found in our iSPERSE PUR1800 and PUR5700 formulations provide a strong intellectual property base for these programs moving forward. Granted composition of matter claims on the active pharmaceutical ingredients when combined with our enabling iSPERSE platform technology support our proprietary approach to improve outcomes in COPD and IPF patients," said Robert Clarke, Ph.D., chief executive officer of Pulmatrix.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, inhaled anti-fungal itraconazole for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases including asthma and chronic obstructive pulmonary disease ("COPD"). Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K filed by the Company with the Securities and Exchange Commission on March 13, 2018, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Robert Clarke, CEO
William Duke, CFO
View original content to download multimedia:http://www.prnewswire.com/news-releases/pulmatrix-receives-five-patents-supporting-claims-for-their-novel-inhaled-narrow-spectrum-kinase-inhibitor-programs-300793580.html
SOURCE Pulmatrix, Inc.